Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target

Area of Science:

• Neuroimmunology
• Central Nervous System Disorders

Background:

• Multiple sclerosis (MS) is a chronic CNS inflammatory disease.
• Myelin sheath destruction leads to neuronal damage and brain lesions.
• Immune mechanisms, particularly aberrant lymphocyte activity, drive MS pathogenesis.

Purpose of the Study:

• To review the aberrant function and count of lymphocytes in MS.
• To elucidate the contribution of lymphocytes to MS mechanisms.
• To outline novel therapeutics targeting lymphocyte dysfunction in MS.

Main Methods:

• Literature review of immunological mechanisms in MS.
• Analysis of lymphocyte populations (Th1, Th17, B cells, Treg, Th9) in MS.
• Summary of current and emerging therapeutic strategies.

Main Results:

• Th1 and Th17 lymphocytes are key in MS pathogenesis, facilitating CNS infiltration and myelin targeting.
• B-lymphocytes contribute via anti-myelin antibodies.
• Aberrant Treg and Th9 cell function also plays a role in MS.

Conclusions:

• Lymphocyte dysregulation is central to multiple sclerosis pathology.
• Understanding these immune cell contributions informs therapeutic development.
• Novel treatments focus on modulating aberrant lymphocyte function and counts for MS management.